Focus on New NanoVators: Welcoming Our Latest Talents at NanoVation Therapeutics (NTx) We are thrilled to introduce the latest additions to our NTx family! Please join us in welcoming Ariane Miriam Nissenbaum, Atul Kaushik Rangadurai, PhD, Ardalan Nabi, and Tony Cheung. Each of them brings their unique personality, passion and expertise in RNA, Chemistry and Finance to our team. We are excited to see the innovative contributions they will make. Want to join us in developing tomorrow's genetic medicines: https://lnkd.in/ePpS-_tM
NanoVation Therapeutics™’s Post
More Relevant Posts
-
✨ The B6-HATXN3 mouse model is a significant advancement in SCA3 research, offering crucial insights into the genetic mutations causing spinocerebellar ataxia type 3. ✅ This model closely mirrors SCA3's pathology, aiding in preclinical studies, biomarker identification, and therapy evaluation. ✅ The TurboKnockout technology enhances its versatility for genetic diversity representation in patients, supporting drug screening and pharmacological studies. Cyagen's introduction of the B6-HATXN3 model highlights their commitment to medical research progress in SCA3 treatment. Learn more about this mouse model here: https://lnkd.in/d9iRFQmr #mousemodels #preclinicalresearch #research #science #biotech #biotechnology #genetherapy
To view or add a comment, sign in
-
Adenine base editors, such as ABE7.10, enable programmable C•G to T•A point mutations, but editing efficiencies can be low at challenging loci in primary human cells. 🧬 Discover how Beam Therapeutics leveraged DNA variant libraries of adenine base editors, synthesized by Ranomics, to evolve ABE7.10 into the ABE8s with superior editing performance 👉 https://lnkd.in/gAJCq7TJ #beamtherapeutics #crisprcas9 #geneediting #genetherapy #geneticengineering #dna
To view or add a comment, sign in
-
MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic
To view or add a comment, sign in
-
Manager of Technical Support at GENCEFE BIOTECH PCR Primer& Probe Design #Gene synthesis #SiRNA Synthesis
MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic
MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic
To view or add a comment, sign in
-
Business Development Manager at GENCEFE BIOTECH #CRO services/Oligonucleotide Synthesis/Gene Synthesis/Protein Expression/Plasmid Preparation
MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. #MicroRNA #miRNA #RNAsynthesis #syntheticbiology #Biotech
MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic
To view or add a comment, sign in
-
New results demonstrate the power of the structure-guided fragment-based approach for identifying binders for classes of proteins that are otherwise generally considered intractable for drug discovery. Our new preprint highlights the direct targeting of brachyury, a historically undruggable target, by small molecules. Read more: https://lnkd.in/g72ebV86
To view or add a comment, sign in
-
It is indeed an honour to present our poster on the 15th Wädenswil Day of Life Sciences: 6th June 2024 at the symposium “Competencies in Drug Discovery” in Zurich, titled: “Strategic in silico pipeline for PROTAC screening: validation with CRBN-RN6-BRD4”. We showcase our integrated computational & bioinformatics pipeline-guided evaluation of therapeutic targets and design of PROTAC molecules with emphasis on linker chemistry. PROTACs are the hottest therapeutic modalities to tackle undruggable targets where SMs fail to show the expected therapeutic outcome. BRD4 is a classic example of a potential anti-cancer target; PROTAC-mediated targeting of BRD4 has proven beneficial over SMs. Our pipeline aids in the identification of an optimal preclinical model for efficacy and safety/tox study. We provide a way forward in predicting the impact of deubiquitinating to estimate the therapeutic area-specific efficacy of the designed PROTACs. We are excited to meet you at the poster session! To download the poster,click: https://lnkd.in/gAEuSc5j #ZHAW #Insilico #Bioinformatics #Cancer #PROTAC #DrugDiscovery #Integratedpipeline #TCGLifeSciences #DataScience #BRD4 #DUB #Efficacy #Toxicity Sohini Basu, Snigdha Patel, Nivedita Dharwar, Anupama Goyal, Sonali Das, Joaquim Figueiredo
To view or add a comment, sign in
-
Network Medicines™ are a new class of therapeutic with the potential to transform the treatment of complex diseases that are driven by multicellular networks, such as #cancer and #fibrosis. They are designed to have both a direct effect by targeting diseased cells themselves and a network effect by reprogramming diseased cells to release therapeutic signals that coordinate other key cells in the network to restore health. Read more about Network Medicines as well as some of the other new science being pioneered by fellow #FlagshipFounded companies below.
Swipe through our newest Flagship Flashcards to learn how #FlagshipFounded companies are pioneering new science including somatic genomics (Quotient Therapeutics), genetic chemistry (Empress Therapeutics), and Network Medicines™ (Sonata Therapeutics) to advance the discovery and development of novel therapeutics. Flip through more Flagship Flashcards: https://bit.ly/3FI16LQ
To view or add a comment, sign in
-
Antibody-conjugated oligonucleotides are revolutionizing the field of genetic medicine with improvements in selectivity, targetability, and overall safety profiles. However, the unique mechanisms of action for these novel modalities present additional challenges and considerations for safety assessment. Join co-chairs Sheroy Minocherhomji and Eileen Blasi to review case studies, discuss unique technical challenges, and learn safety development strategies for these novel oligonucleotide therapeutics in Symposium S08 at ACT's 2024 Annual Meeting titled "Hitching a Ride to Transduce Barriers: Nonclinical Safety Considerations for Developing Transcriptome Modulating Therapies". Link for registration to the Annual meeting: lnkd.in/ek5UQRza
To view or add a comment, sign in
-
Exciting news in AI-driven drug development! Iambic Therapeutics, an innovative AI biotech, is advancing into clinical trials with a focus on HER2 cancers. Their cutting-edge approach showcases yet another way in which AI-driven platforms will revolutionize healthcare. #AI #HealthcareInnovation #DrugDevelopment #PrecisionMedicine
The rapid path to the clinic for our lead oncology candidate, IAM1363, benefited from the remarkable insights drawn from our state-of-the-art AI NeuralPLexer and OrbNet models for drug discovery, and the protein-ligand complexes and the associated conformational changes from interactions with drug molecules that they predicted. This enabled us to advance from discovery into human studies, in just 24 months, a highly selective and brain-penetrant small molecule inhibitor of HER2 signaling, for which we will present new data at this week’s AACR meeting in San Diego. Thank you to Genetic Engineering & Biotechnology News for this comprehensive article highlighting the recent advances in our AI drug-discovery models, as well as our important technical collaborations and drug development efforts. #AI #DrugDiscovery #AACR https://lnkd.in/d2CUCc7c
To view or add a comment, sign in
8,059 followers